{"id":70872,"date":"2026-07-29T18:20:10","date_gmt":"2026-07-29T10:20:10","guid":{"rendered":"https:\/\/flcube.com\/?p=70872"},"modified":"2026-07-29T18:20:12","modified_gmt":"2026-07-29T10:20:12","slug":"astrazenecas-ultomiris-fails-primary-endpoint-in-adult-hsct-tma-phase-iii-trial-despite-positive-pediatric-data","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70872","title":{"rendered":"AstraZeneca&#8217;s Ultomiris Fails Primary Endpoint in Adult HSCT-TMA Phase III Trial Despite Positive Pediatric Data"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>AstraZeneca plc<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/AZN:NYSE\">NYSE: AZN<\/a>) announced that its <strong>ALXN1210-TMA-313 Phase III clinical trial<\/strong> failed to meet statistical significance for the primary endpoint of <strong>event-free survival through 26 weeks<\/strong> when comparing <strong>Ultomiris (ravulizumab)<\/strong> to placebo in adults and adolescents with <strong>thrombotic microangiopathy after haematopoietic stem cell transplant (HSCT-TMA)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-results-overview\" class=\"wp-block-heading\">Clinical Trial Results Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>AstraZeneca plc (NYSE: AZN) \/ Alexion, AstraZeneca Rare Disease<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>Ultomiris (ravulizumab)<\/td><\/tr><tr><td><strong>Trial ID<\/strong><\/td><td>ALXN1210-TMA-313<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>HSCT-TMA in adults and adolescents (\u226512 years)<\/td><\/tr><tr><td><strong>Trial Design<\/strong><\/td><td>Randomized, placebo-controlled Phase III<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Event-free survival through 26 weeks (time to TMA-related clinical worsening or death)<\/td><\/tr><tr><td><strong>Result<\/strong><\/td><td>Did not achieve statistical significance vs. placebo<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>29 Jul 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-current-indications\" class=\"wp-block-heading\">Drug Profile &amp; Current Indications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>Longest-acting C5 complement inhibitor<\/strong> with extended dosing intervals<\/li>\n\n\n\n<li><strong>Current Approvals:<\/strong><\/li>\n\n\n\n<li>Paroxysmal nocturnal haemoglobinuria (PNH)<\/li>\n\n\n\n<li>Atypical haemolytic uraemic syndrome (aHUS)<\/li>\n\n\n\n<li>Generalised myasthenia gravis (gMG)<\/li>\n\n\n\n<li>Neuromyelitis optica spectrum disorder (NMOSD)<\/li>\n\n\n\n<li><strong>Development Focus:<\/strong> Expanding into rare hematologic disorders including HSCT-TMA<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-contrasting-pediatric-results\" class=\"wp-block-heading\">Contrasting Pediatric Results<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Despite the negative adult\/adolescent data, <strong>pediatric outcomes remain promising<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Trial:<\/strong> ALXN1210-TMA-314 open-label Phase III in pediatric patients<\/li>\n\n\n\n<li><strong>26-week Overall Survival:<\/strong> <strong>87.2%<\/strong> (clinically meaningful)<\/li>\n\n\n\n<li><strong>52-week Overall Survival:<\/strong> <strong>73.4%<\/strong><\/li>\n\n\n\n<li><strong>Regulatory Status:<\/strong> Alexion advancing regulatory filings for pediatric HSCT-TMA indication<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This stark contrast between adult and pediatric populations suggests potential age-related differences in disease pathophysiology or treatment response mechanisms.<\/p>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<h3 id=\"h-for-astrazeneca\" class=\"wp-block-heading\">For AstraZeneca<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pediatric Priority:<\/strong> Continued focus on pediatric HSCT-TMA regulatory submissions represents a viable commercial pathway<\/li>\n\n\n\n<li><strong>Adult Strategy:<\/strong> Ongoing discussions with health authorities to interpret adult trial data and determine next steps<\/li>\n\n\n\n<li><strong>Portfolio Impact:<\/strong> Ultomiris remains a key growth driver in AstraZeneca&#8217;s rare disease portfolio despite this setback<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-market-context\" class=\"wp-block-heading\">Market Context<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HSCT-TMA Burden:<\/strong> Thrombotic microangiopathy affects 10-35% of HSCT recipients with mortality rates up to 80%<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> No approved therapies currently exist for HSCT-TMA, representing significant unmet medical need<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Limited competition in this ultra-rare indication, but high development risk due to patient heterogeneity<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-forward-path\" class=\"wp-block-heading\">Forward Path<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Alexion, AstraZeneca Rare Disease is maintaining its commitment to HSCT-TMA patients by:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Continuing regulatory engagement for pediatric indication<\/li>\n\n\n\n<li>Conducting comprehensive data analysis of adult trial results<\/li>\n\n\n\n<li>Exploring potential biomarker-driven patient selection strategies for future studies<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory submissions, and commercial expectations. Actual results may differ due to regulatory decisions, competitive developments, and interpretation of clinical data.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca plc (NYSE: AZN) announced that its ALXN1210-TMA-313 Phase III clinical trial failed to meet&#8230;<\/p>\n","protected":false},"author":1,"featured_media":70873,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[130,17,4621,24],"class_list":["post-70872","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-astrazeneca","tag-clinical-trial-results","tag-nyse-azn","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AstraZeneca&#039;s Ultomiris Fails Primary Endpoint in Adult HSCT-TMA Phase III Trial Despite Positive Pediatric Data - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AstraZeneca plc (NYSE: AZN) announced that its ALXN1210-TMA-313 Phase III clinical trial failed to meet statistical significance for the primary endpoint of event-free survival through 26 weeks when comparing Ultomiris (ravulizumab) to placebo in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplant (HSCT-TMA).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70872\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca&#039;s Ultomiris Fails Primary Endpoint in Adult HSCT-TMA Phase III Trial Despite Positive Pediatric Data\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca plc (NYSE: AZN) announced that its ALXN1210-TMA-313 Phase III clinical trial failed to meet statistical significance for the primary endpoint of event-free survival through 26 weeks when comparing Ultomiris (ravulizumab) to placebo in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplant (HSCT-TMA).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70872\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-29T10:20:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-29T10:20:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2901.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70872#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70872\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca&#8217;s Ultomiris Fails Primary Endpoint in Adult HSCT-TMA Phase III Trial Despite Positive Pediatric Data\",\"datePublished\":\"2026-07-29T10:20:10+00:00\",\"dateModified\":\"2026-07-29T10:20:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70872\"},\"wordCount\":393,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70872#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2901.webp\",\"keywords\":[\"AstraZeneca\",\"Clinical trial results\",\"NYSE:\u202fAZN\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70872#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70872\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70872\",\"name\":\"AstraZeneca's Ultomiris Fails Primary Endpoint in Adult HSCT-TMA Phase III Trial Despite Positive Pediatric Data - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70872#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70872#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2901.webp\",\"datePublished\":\"2026-07-29T10:20:10+00:00\",\"dateModified\":\"2026-07-29T10:20:12+00:00\",\"description\":\"AstraZeneca plc (NYSE: AZN) announced that its ALXN1210-TMA-313 Phase III clinical trial failed to meet statistical significance for the primary endpoint of event-free survival through 26 weeks when comparing Ultomiris (ravulizumab) to placebo in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplant (HSCT-TMA).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70872#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70872\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70872#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2901.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2901.webp\",\"width\":1080,\"height\":608,\"caption\":\"AstraZeneca's Ultomiris Fails Primary Endpoint in Adult HSCT-TMA Phase III Trial Despite Positive Pediatric Data\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70872#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca&#8217;s Ultomiris Fails Primary Endpoint in Adult HSCT-TMA Phase III Trial Despite Positive Pediatric Data\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca's Ultomiris Fails Primary Endpoint in Adult HSCT-TMA Phase III Trial Despite Positive Pediatric Data - Insight, China&#039;s Pharmaceutical Industry","description":"AstraZeneca plc (NYSE: AZN) announced that its ALXN1210-TMA-313 Phase III clinical trial failed to meet statistical significance for the primary endpoint of event-free survival through 26 weeks when comparing Ultomiris (ravulizumab) to placebo in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplant (HSCT-TMA).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70872","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca's Ultomiris Fails Primary Endpoint in Adult HSCT-TMA Phase III Trial Despite Positive Pediatric Data","og_description":"AstraZeneca plc (NYSE: AZN) announced that its ALXN1210-TMA-313 Phase III clinical trial failed to meet statistical significance for the primary endpoint of event-free survival through 26 weeks when comparing Ultomiris (ravulizumab) to placebo in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplant (HSCT-TMA).","og_url":"https:\/\/flcube.com\/?p=70872","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-29T10:20:10+00:00","article_modified_time":"2026-07-29T10:20:12+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2901.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70872#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70872"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca&#8217;s Ultomiris Fails Primary Endpoint in Adult HSCT-TMA Phase III Trial Despite Positive Pediatric Data","datePublished":"2026-07-29T10:20:10+00:00","dateModified":"2026-07-29T10:20:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70872"},"wordCount":393,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=70872#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2901.webp","keywords":["AstraZeneca","Clinical trial results","NYSE:\u202fAZN","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70872#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70872","url":"https:\/\/flcube.com\/?p=70872","name":"AstraZeneca's Ultomiris Fails Primary Endpoint in Adult HSCT-TMA Phase III Trial Despite Positive Pediatric Data - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=70872#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=70872#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2901.webp","datePublished":"2026-07-29T10:20:10+00:00","dateModified":"2026-07-29T10:20:12+00:00","description":"AstraZeneca plc (NYSE: AZN) announced that its ALXN1210-TMA-313 Phase III clinical trial failed to meet statistical significance for the primary endpoint of event-free survival through 26 weeks when comparing Ultomiris (ravulizumab) to placebo in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplant (HSCT-TMA).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70872#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70872"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=70872#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2901.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2901.webp","width":1080,"height":608,"caption":"AstraZeneca's Ultomiris Fails Primary Endpoint in Adult HSCT-TMA Phase III Trial Despite Positive Pediatric Data"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70872#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca&#8217;s Ultomiris Fails Primary Endpoint in Adult HSCT-TMA Phase III Trial Despite Positive Pediatric Data"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2901.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70872","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70872"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70872\/revisions"}],"predecessor-version":[{"id":70874,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70872\/revisions\/70874"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/70873"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70872"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70872"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70872"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}